Litigation Details for WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)

WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)

Docket		Date Filed	2012-08-15
Court	District Court, District of Columbia	Date Terminated
Cause	05:702 Administrative Procedure Act	Assigned To	Amy Berman Jackson
Jury Demand	None	Referred To
Parties	KATHLEEN SEBELIUS
Patents	6,150,383; 6,150,384; 6,166,042; 6,166,043; 6,172,090; 6,211,205; 6,271,243; 6,303,640; 6,329,404
Attorneys	Margaret L. Woodland
Firms	Axinn Veltrop & Harkrider, LLP
Link to Docket	External link to docket

Details for WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-08-15	1		pioglitazone’s use as a combination therapy (U.S. Patent Nos. 6,150,383, 6,150,384, 6,166,042, 6,166,043, 6,172,090…U.S. Patent Nos. 5,965,584 and 6,329,404) (collectively, the “Composition Patents”) and patents relating…name drug manufacturer should submit patent information – the patent’s number and its expiration date –…manufacturer has not filed patent information with FDA; or, for each patent listed in the Orange Book …seeking approval, (ii) that the patent has expired; (iii) that the patent expires on a date before which	External link to document
2012-10-22	53		; 6,172,090; 6,150,383; and 6,150,384. Brannan Decl. ¶ 11. Watson refers to these patents as “Combination… IV Composition/Use 6,150,383 Use-only IV … IV Composition/Use 6,150,383 Use-only viii … Combination Therapy Patents.”). 4 The use-only patents are U.S. Patent Nos. 6,211,205; 6,271,243…Combination Therapy” patents. Id. 5 The drug composition/use patents are U.S. Patent Nos. 5,965,584 and	External link to document